Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Kerry L. Reynolds"'
Autor:
Ayo S. Falade, Kerry L. Reynolds, Leyre Zubiri, Vikram Deshpande, Florian J. Fintelmann, Michael Dougan, Meghan J. Mooradian
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Since the first approval of immune checkpoint inhibitors (ICIs) in 2011, these agents have rapidly become an integral treatment option across tumor types. However, with the increased adoption of ICIs, the incidence of immune-related adverse events (i
Externí odkaz:
https://doaj.org/article/d0ff8795a65a4f67827571a1d51912d6
Autor:
Harish Seethapathy, Sophia Zhao, Ian A. Strohbehn, Meghan Lee, Donald F. Chute, Halla Bates, Gabriel E. Molina, Leyre Zubiri, Shruti Gupta, Shveta Motwani, David E. Leaf, Ryan J. Sullivan, Osama Rahma, Kimberly G. Blumenthal, Alexandra-Chloe Villani, Kerry L. Reynolds, Meghan E. Sise
Publikováno v:
Kidney International Reports, Vol 5, Iss 10, Pp 1700-1705 (2020)
Background: Programmed cell death receptor ligand 1 (PD-L1) inhibitors are immune checkpoint inhibitors (ICIs) with a side effect profile that may differ from other classes of ICIs such as those directed against cytotoxic T-lymphocyte−associated pr
Externí odkaz:
https://doaj.org/article/e8904d035ea34b23aca56820cb203d19
Autor:
Michael S. Hughes, Hui Zheng, Leyre Zubiri, Gabriel E. Molina, Steven T. Chen, Meghan J. Mooradian, Ian M. Allen, Kerry L. Reynolds, Michael Dougan
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 4986-4999 (2019)
Abstract Background Immune checkpoint inhibitors (CPIs) have revolutionized oncologic therapy but can lead to immune‐related adverse events (irAEs). Corticosteroids are first‐line treatment with escalation to biologic immunosuppression in refract
Externí odkaz:
https://doaj.org/article/dc34be1618d34608b433f3de2ca9f4c9
Autor:
Andrew J. Piper-Vallillo, MD, Meghan J. Mooradian, MD, Catherine B. Meador, MD, PhD, Beow Y. Yeap, ScD, Jennifer Peterson, BS, Mustafa Sakhi, BS, MS, Andrew Do, BS, Leyre Zubiri, MD, Sara Stevens, NP, Jeanne Vaughn, NP, Kelly Goodwin, NP, Alexander Gavralidis, MD, Henning Willers, MD, Adam Miller, MD, Anna Farago, MD, PhD, Zofia Piotrowska, MD, MHS, Jessica J. Lin, MD, Ibiayi Dagogo-Jack, MD, Inga T. Lennes, MD, MPH, MBA, Lecia V. Sequist, MD, MPH, Jennifer S. Temel, MD, Rebecca S. Heist, MD, Subba Digumarthy, MD, Kerry L. Reynolds, MD, Justin F. Gainor, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100124- (2021)
Introduction: Lung cancer is associated with severe coronavirus disease 2019 (COVID-19) infections. Symptom overlap between COVID-19 and lung cancer may complicate diagnostic evaluation. We aimed to investigate the incidence, symptoms, differential d
Externí odkaz:
https://doaj.org/article/899d24b36a34456388b6d820eedce98b
Autor:
Zsofia D. Drobni, Amna Zafar, Leyre Zubiri, Daniel A. Zlotoff, Raza M. Alvi, Charlotte Lee, Sarah Hartmann, Hannah K. Gilman, Alexandra‐Chloe Villani, Anju Nohria, John D. Groarke, Ryan J. Sullivan, Kerry L. Reynolds, Lili Zhang, Tomas G. Neilan
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 23 (2020)
Background Myocarditis attributable to immune checkpoint inhibitor (ICI) therapy is a potentially fatal immune‐related adverse event. Limited data have suggested an association between baseline and on‐treatment absolute lymphocyte count (ALC) and
Externí odkaz:
https://doaj.org/article/c28be87d197a4243bd78d7f461016d21
Autor:
Laura C Cappelli, Bernice Kwong, Jarushka Naidoo, Jonathan Leventhal, Mario E Lacouture, Meghan J Mooradian, Douglas B Johnson, Justine Cohen, Aparna Hegde, Steven T Chen, Riley Fadden, Leyre Zubiri, Shawn Kwatra, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Yevgeniy R Semenov, Nicole R LeBoeuf, Krista M Rubin, Anna K Dewan, Alina Markova, Allireza Alloo, Daniel Q Bach, Amina Bougrine, Leeann Burton, Mariana Castells, Lauren Guggina, Victor Huang, Benjamin Kaffenberger, Daniela Kroshinsky, Cecilia Larocca, Jon McDunn, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Maxwell Sauder, Sheila Shaigany, Afreen Shariff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest,
Externí odkaz:
https://doaj.org/article/0f9ad47d419c4ad4b3131ec90c49be9f
Autor:
Benjamin C. Park, Sathya Narayanan, Alexander Gavralidis, Fei Ye, Run Fan, Ryan J. Sullivan, Genevieve Boland, Kerry L Reynolds, Justin M. Balko, Matteo S. Carlino, Georgina V. Long, Leyre Zubiri, Alexander M. Menzies, Douglas B. Johnson
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTImmune-related adverse events (irAEs) are side effects of immune checkpoint inhibitor therapy (ICI). While common irAEs have been well characterized, there are more limited data on rare immune related adverse events (RirAEs) due to low incide
Externí odkaz:
https://doaj.org/article/5fea4b8fffe544958754d98c4b9d90c4
Autor:
Sandra M Herrmann, Riley Fadden, Ryan J Sullivan, Kerry L Reynolds, Harish Seethapathy, Meghan E Sise, Shruti Gupta, Alexandra-Chloe Villani, Qiyu Wang, Daiana Moreno, Destiny Harden, R Neal Smith, Ivy A Rosales, Robert B Colvin, Sarah Chute, Lynn D Cornell, Nancy J Yang, Sara Barmettler, Sophia Wells, Jocelyn Farmer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Non-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4),
Externí odkaz:
https://doaj.org/article/b2896a0a2c844123a9938a6aff85c060
Autor:
Joe-Elie Salem, Enriqueta Felip, Shuchi Anand, Karolina Benesova, Marlies Ostermann, Ala Abudayyeh, Omar Mamlouk, Umut Selamet, Grace Cherry, Sunandana Chandra, Sandra M Herrmann, Maria Jose Soler, Abhijat Kitchlu, Jamie S Lin, Kerry L Reynolds, Elizabeth M Gaughan, Eva Muñoz-Couselo, Jamie S Hirsch, Pablo Garcia, Meghan E Sise, Thibaud Koessler, Mark Eijgelsheim, Shruti Gupta, Frank B Cortazar, Jason M Prosek, Ilya Glezerman, Shveta S Motwani, Naoka Murakami, Rimda Wanchoo, David I Ortiz-Melo, Arash Rashidi, Ben Sprangers, Vikram Aggarwal, A Bilal Malik, Sebastian Loew, Christopher A Carlos, Pazit Beckerman, Zain Mithani, Chintan V Shah, Amanda D Renaghan, Sophie De Seigneux, Luca Campedel, Daniel Sanghoon Shin, Sunil Rangarajan, Priya Deshpande, Gaia Coppock, Marium Husain, Clara Garcia-Carro, Sheila Bermejo, Nuttha Lumlertgul, Nina Seylanova, Busra Isik, Aydin Kaghazchi, Yuriy Khanin, Sheru K Kansal, Kai M Schmidt-Ott, Raymond K Hsu, Maria C Tio, Harkarandeep Singh, Kenar D Jhaveri, David E Leaf, Corinne Isnard Bagnis, Suraj S Mothi, Weiting Chang, Vipulbhai Sakhiya, Daniel Stalbow, Sylvia Wu, Armando Cennamo, Anne Rigg, Nisha Shaunak, Zoe A Kibbelaar, Harish S Seethapathy, Meghan Lee, Ian A Strohbhen, Ilya G Glezerman, Dwight H Owen, Sharon Mini, Andrey Kisel, Nicole Albert, Katherine Carter, Vicki Donley, Tricia Young, Heather Cigoi, Els Wauters Ben Sprangers, Javier A Pagan, Jonathan J Hogan, Valda Page, Samuel AP Short, Maria Josep Carreras, Sethu M. Madhavan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adve
Externí odkaz:
https://doaj.org/article/a6f6e1b57fb14e89bf208b6a482d2a1a
Autor:
Jarushka Naidoo, Ryan Sullivan, Meghan J Mooradian, Leyre Zubiri, Vartan Pahalyants, Nicholas Theodosakis, Kerry L Reynolds, Yevgeniy R Semenov, Meghan E Sise, James Iheke, Pearl Ugwu-Dike, Jayhyun Seo, Kimberly Tang, Bruce C Tiu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/e69c94c662834802beab88009e05effd